Patent · US Active

Respiratory syncytial virus (RSV) vaccine

US11739125B2 · kind B2 · utility

6Cited by

127References

15Claims

0Family size

Assignee

CureVac SE · DE

Inventors

Thomas Kramps · Bellinzona, CH
Margit SCHNEE · Konstanz, DE
Daniel Voss · Tübingen, DE
Benjamin PETSCH · Tübingen, DE

Key dates

Filing date	May 11, 2021
Grant date	Aug 29, 2023
Priority date	—
Expiry date	May 11, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18534
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.